Designing Better GLP-1 Drug Delivery: From Molecular Structure to Advanced Formulations | Research

The takeaway

GLP-1 drug delivery has advanced through structural modifications and formulation innovations to overcome the natural peptide's rapid degradation by DPP-IV.

Minutes to weeks
Structural and delivery innovations extended GLP-1 drug activity from minutes (native peptide) to once-weekly dosing

What the researchers found

Various structural modifications and delivery strategies have successfully overcome GLP-1's fragility, enabling the development of long-acting and orally available GLP-1 therapeutics.

Why it matters

Understanding how GLP-1 drugs were engineered explains why different formulations exist and informs the development of next-generation versions with even better convenience and efficacy.

The numbers in context

Reviews N-terminal, C-terminal, fatty acid side chain, and large molecule conjugation modifications. Discusses half-life extension, receptor binding, and bioactivity improvements.

How the study worked

Comprehensive review of GLP-1 structural biology, DPP-IV resistance strategies, pharmacokinetic modifications, and advanced drug delivery formulation approaches.

Who was studied

Not applicable (pharmaceutical science review)

What this study cannot tell us

Review article — does not provide new experimental data. Some discussed delivery approaches are still experimental.

How to read the evidence

Comprehensive review of established and emerging drug delivery science. Well-supported by decades of published research.

When this study was published

Published in 2025, providing an up-to-date overview of GLP-1 delivery technology including the latest formulation advances.

The bigger picture

The GLP-1 drug development story is a masterclass in peptide engineering — turning a fragile natural hormone into one of the most successful drug classes in medicine.

Questions still open

What delivery innovations will enable the next generation of GLP-1 drugs?
Can implantable or long-acting depot formulations extend dosing to monthly or beyond?

Common questions

Why cannot you just swallow natural GLP-1?

Natural GLP-1 is destroyed by the enzyme DPP-IV within minutes and would also be degraded by digestive enzymes if swallowed. The drugs available today use chemical modifications to resist these enzymes, and special formulations (like oral semaglutide) use absorption enhancers to survive the gut.

Will there be monthly or longer-acting GLP-1 drugs?

Research is moving in that direction. Advanced delivery systems including implants and depot formulations are being developed that could extend dosing intervals beyond weekly, improving convenience for patients.

Read the original research

Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.

Nutrition & diabetes, 15(1), 53

View on PubMed ↗Publisher’s paper ↗

Citation

Peri, Ravi Vamsi; Anchan, Harsh; Jonnalagadda, Kamal; Varghese, Ryan; Gupta, Pardeep. (2025). Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.. Nutrition & diabetes, 15(1), 53. https://doi.org/10.1038/s41387-025-00397-4